Shopping Cart
- Remove All
Your shopping cart is currently empty
NKY80 regulates the adenylyl cyclase catalytic activity in heart and lung tissues. NKY80 is a non-competitive inhibitor of adenylyl cyclase type V isoform (IC50s: 8.3 µM, 132 µM, and 1.7 mM for type V, III and II, respectively).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $39 | In Stock | |
| 5 mg | $62 | In Stock | |
| 10 mg | $97 | In Stock | |
| 25 mg | $197 | In Stock | |
| 50 mg | $343 | In Stock | |
| 100 mg | $523 | In Stock | |
| 200 mg | $753 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $107 | In Stock |
| Description | NKY80 regulates the adenylyl cyclase catalytic activity in heart and lung tissues. NKY80 is a non-competitive inhibitor of adenylyl cyclase type V isoform (IC50s: 8.3 µM, 132 µM, and 1.7 mM for type V, III and II, respectively). |
| Targets&IC50 | AC type V:8.3 μM, AC type II:1.7 mM, AC type III:132 μM |
| In vitro | NKY80 (20 μM) blocks the increase in LVP and ventricular cAMP levels[2]. NKY80 (20 μM; 2 hours) completely blocks the elevations in both cAMP content and renin release from isolated JG cells[3]. |
| Synonyms | Adenylyl cyclase type V Inhibitor |
| Molecular Weight | 229.23 |
| Formula | C12H11N3O2 |
| Cas No. | 299442-43-6 |
| Smiles | NC1=NC2=C(C=N1)C(=O)CC(C2)C1=CC=CO1 |
| Relative Density. | 1.360 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 225 mg/mL (981.5 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (21.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.